Home > Insider Trading > Filing (0001567619-21-003189)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1601485	Angion Biomedica Corp.	ANGN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1199070	F Victor Ganzi	C/O Angion Biomedica Corp. 51 Charles Lindbergh Blvd. Uniondale NY 11553		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-09	18,741	$11.57	405,405	No	4	C	Direct
Common Stock	Acquisiton	2021-02-09	50,122	$11.57	455,527	No	4	C	Direct
Common Stock	Acquisiton	2021-02-09	367,590	$6.43	823,117	No	4	X	Direct
Common Stock	Disposition	2021-02-09	246,720	$16.00	576,397	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	X	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Convertible Promissory Note	Disposition	2021-02-09	0	$0.00	216,833	$16.00
Common Stock	Convertible Promissory Note	Disposition	2021-02-09	0	$0.00	0	$16.00
Common Stock	Warrant to Purchase Common Stock	Disposition	2021-02-09	367,590	$0.00	367,590	$6.43

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
	No	4	C	Direct
	No	4	C	Direct
2028-07-05	No	4	X	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	155,581	Indirect	Trust

Footnotes

Victor F. Ganzi 2012 GST Family Trust.
On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 614,310 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's IPO price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's IPO, the Issuer withheld 246,720 of the warrant shares to pay the exercise price and issued the remaining 367,590 shares of common stock to Reporting Person.
The convertible promissory note converted immediately prior to the consummation of the IPO into Common Stock.
The convertible promissory note ("Convertible Note") had a maturity date of May 28, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share.
The convertible promissory note ("Convertible Note") had a maturity date of August 21, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share.